Phospho-GRIN2B (Ser1303) Antibody

What is the significance of Ser1303 phosphorylation in GRIN2B?

Ser1303 phosphorylation represents a critical post-translational modification site on the GluN2B subunit (encoded by GRIN2B) of NMDA receptors. This phosphorylation event occurs within the C-terminal region of the protein (amino acids 1269-1318) and plays a significant role in regulating receptor function and trafficking. Phosphorylation at this site has been implicated in synaptic plasticity mechanisms, including long-term potentiation and depression, which underlie learning and memory processes. Additionally, abnormal phosphorylation at Ser1303 has been associated with various neurological conditions, making it an important target for researchers investigating NMDA receptor regulation in normal and pathological states .

How specific is the Phospho-GRIN2B (Ser1303) Antibody?

The Anti-GRIN2B (phospho Ser1303) Antibody is highly specific, designed to detect endogenous levels of GRIN2B protein only when phosphorylated at Ser1303. This specificity is achieved through careful immunogen design and purification processes. The antibody is typically generated using a synthetic peptide derived from human GRIN2B around the phosphorylation site of Ser1303 (specifically amino acids 1269-1318) and is purified through antigen affinity chromatography using the immunizing phospho peptide. This rigorous production process ensures that the antibody binds selectively to the phosphorylated form of GRIN2B at Ser1303 without cross-reactivity to the non-phosphorylated form or other phosphorylation sites .

What are the optimal storage conditions for maintaining antibody activity?

For optimal preservation of antibody activity, the Phospho-GRIN2B (Ser1303) Antibody should be shipped at 4°C and, upon delivery, immediately aliquoted and stored at -20°C. Multiple freeze-thaw cycles should be strictly avoided as they can significantly degrade antibody performance. The antibody is typically formulated in Phosphate Buffered Saline (without Mg²⁺ and Ca²⁺), pH 7.4, with 150mM NaCl, 0.02% Sodium Azide, and 50% Glycerol to maintain stability. This formulation provides protection during freeze-thaw transitions when they do occur. For long-term storage exceeding 6 months, consider storing small aliquots at -80°C to further minimize potential degradation .

What are the validated applications for Phospho-GRIN2B (Ser1303) Antibody?

The Phospho-GRIN2B (Ser1303) Antibody has been validated for several experimental applications with specific recommended dilutions for each technique:

When designing experiments, it's essential to perform preliminary titration experiments to determine the optimal antibody concentration for your specific experimental conditions and sample types. The antibody demonstrates reactivity across human, mouse, and rat samples, making it versatile for comparative studies across these species .

How should I design Western blot experiments to detect phosphorylated GRIN2B at Ser1303?

For optimal Western blot detection of phosphorylated GRIN2B at Ser1303, implement the following methodological approach:

• Sample preparation: Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, and β-glycerophosphate) in your lysis buffer to preserve phosphorylation status.

• Control selection: Include both phosphatase-treated samples and total GRIN2B antibody detection in parallel blots to confirm phospho-specificity.

• Gel selection: Use 6-8% SDS-PAGE gels to achieve adequate separation of the high molecular weight GRIN2B protein (166kDa).

• Transfer conditions: Implement extended transfer times (overnight at low voltage) for efficient transfer of large proteins.

• Blocking: Use 5% BSA in TBST rather than milk (which contains phosphatases that might reduce signal).

• Antibody dilution: Start with a 1:750 dilution in 5% BSA/TBST, adjusting based on preliminary results.

• Detection: Use highly sensitive ECL reagents appropriate for phospho-proteins.

• Normalization: Normalize phospho-signal to total GRIN2B levels rather than housekeeping proteins to account for expression variations .

What are the most common reasons for weak or absent signal when using Phospho-GRIN2B (Ser1303) Antibody?

When encountering weak or absent signals with Phospho-GRIN2B (Ser1303) Antibody, systematically address these potential causes:

• Degraded phosphorylation state: Inadequate phosphatase inhibition during sample preparation can result in dephosphorylation of Ser1303. Ensure fresh phosphatase inhibitors are included in lysis buffers and maintain samples at cold temperatures throughout processing.

• Insufficient antigen amount: GRIN2B expression varies across brain regions and developmental stages, with expression peaking during the third postnatal week in rodents. Increase starting material or enrich for membrane fractions where NMDARs are concentrated.

• Inefficient protein transfer: Large proteins like GRIN2B (166kDa) transfer inefficiently using standard protocols. Extend transfer time or use specialized systems for high molecular weight proteins.

• Antibody degradation: Repeated freeze-thaw cycles diminish antibody performance. Use fresh aliquots and verify antibody activity with positive control samples.

• Suboptimal detection conditions: Phospho-epitopes often require enhanced detection systems. Extend primary antibody incubation time (overnight at 4°C) and utilize high-sensitivity detection reagents.

• Biological variability in phosphorylation: Ser1303 phosphorylation is dynamic and activity-dependent. Consider treatments that enhance phosphorylation (e.g., NMDA receptor activation protocols) for positive controls .

How can I validate the specificity of phospho-signal in my experiments?

To rigorously validate the specificity of your phospho-GRIN2B (Ser1303) signal, implement these methodological controls:

• Phosphatase treatment control: Divide your sample into two aliquots and treat one with lambda phosphatase before immunoblotting. The phospho-specific signal should disappear in the treated sample while total GRIN2B signal (detected with a non-phospho-specific antibody) remains unchanged.

• Blocking peptide competition: Pre-incubate the antibody with excess phospho-peptide immunogen before application to your experimental samples. This should abolish specific binding while a non-phosphorylated peptide control should not affect signal.

• Genetic knockdown/knockout validation: When possible, utilize GRIN2B knockdown or knockout samples, or samples with Ser1303 mutation to alanine (S1303A) as negative controls.

• Stimulation experiments: Employ treatments known to increase Ser1303 phosphorylation (such as NMDA receptor activation or CaMKII activation) compared to basal conditions to demonstrate dynamic range of the antibody.

• Cross-validation with alternative detection methods: Confirm your findings using alternative techniques such as mass spectrometry-based phospho-proteomics or Phos-tag gel electrophoresis .

How does phosphorylation at Ser1303 affect GRIN2B trafficking and function in neurons?

Phosphorylation at Ser1303 of GRIN2B regulates multiple aspects of NMDA receptor dynamics and function through sophisticated mechanisms:

Receptor trafficking: Ser1303 phosphorylation modulates surface expression of NMDA receptors containing GluN2B. Studies utilizing various trafficking assessment methodologies, including surface immunolabeling of unpermeabilized cells, surface biotinylation approaches, and fluorescent reporter methods, have demonstrated that phosphorylation state influences both anterograde trafficking to the plasma membrane and endocytic recycling. Specifically, phosphorylation at this site can stabilize receptors at the cell surface by interfering with endocytosis machinery interactions .

Electrophysiological properties: Ser1303 phosphorylation alters channel gating properties, including open probability and desensitization kinetics. Electrophysiological studies have shown that this phosphorylation can increase channel open time and calcium permeability, thereby enhancing NMDAR-mediated currents. This has significant implications for synaptic plasticity, as increased calcium influx can trigger downstream signaling cascades involved in long-term potentiation .

Protein-protein interactions: The phosphorylation state of Ser1303 influences interactions with scaffolding proteins and cytoskeletal elements. This affects receptor clustering at synapses and localization within specific membrane microdomains, which can ultimately impact synaptic strength and stability .

How can I assess the impact of GRIN2B variants on Ser1303 phosphorylation in experimental models?

To systematically evaluate the impact of GRIN2B variants on Ser1303 phosphorylation, implement this comprehensive experimental framework:

• Heterologous expression systems analysis:

  • Co-express mutant GluN2B with GluN1 in HEK293 cells or Xenopus oocytes

  • Stimulate cells with protocols that induce Ser1303 phosphorylation (e.g., PKC activators)

  • Quantify phosphorylation levels using the Phospho-GRIN2B (Ser1303) Antibody via Western blot and normalize to total GluN2B expression

  • Compare phosphorylation efficiency between wild-type and variant GluN2B

• Primary neuronal culture studies:

  • Transfect hippocampal or cortical neurons with wild-type or mutant GluN2B constructs

  • Assess baseline and activity-dependent phosphorylation at Ser1303

  • Correlate phosphorylation levels with electrophysiological properties and dendritic morphology

  • Several GRIN2B variants (particularly those affecting the C-terminal domain) have been shown to significantly impact dendrite length, complexity, and branching patterns when expressed in neurons

• Structural analysis:

  • Utilize molecular dynamics simulations to predict how variants might alter the accessibility of Ser1303 to kinases

  • Calculate RMSF (Root Mean Square Fluctuation) values to assess protein flexibility differences between wild-type and mutant proteins that might affect kinase binding or phosphorylation efficiency

  • Studies have shown that variants like p.Asn615Ile, p.Thr685Pro, and p.Arg682Cys exhibit different flexibility patterns that could impact phosphorylation dynamics

• In vivo models:

  • Generate knock-in mouse models carrying specific GRIN2B variants

  • Analyze Ser1303 phosphorylation across developmental timepoints and brain regions

  • Correlate phosphorylation changes with behavioral phenotypes relevant to GRIN2B-associated neurodevelopmental disorders

How does Ser1303 phosphorylation relate to GRIN2B-associated neurodevelopmental disorders?

Ser1303 phosphorylation of GRIN2B plays a multifaceted role in GRIN2B-associated neurodevelopmental disorders through several mechanistic pathways:

Dysregulated signaling: Altered phosphorylation at Ser1303 can disrupt the precise balance of NMDA receptor activity required for normal neurodevelopment. Both hypo- and hyper-phosphorylation states can contribute to pathological conditions by affecting calcium influx and downstream signaling cascades critical for synaptic plasticity and neuronal development .

Dendritic development impairment: Proper phosphorylation of GRIN2B at Ser1303 is essential for normal dendritic development. Research has demonstrated that expression of mutant GluN2B can lead to reduced dendrite length, complexity, and abnormal branching patterns. These morphological defects may contribute to the neurological manifestations observed in patients with GRIN2B variants .

Variant-specific effects: Different disease-associated variants in GRIN2B can distinctly affect Ser1303 phosphorylation. Some variants directly interfere with kinase recognition sites, while others induce conformational changes that indirectly alter phosphorylation efficiency. For example, variants like p.Asn615Ile exhibit altered structural flexibility that may impact phosphorylation-dependent signaling .

Developmental timing: The consequences of abnormal Ser1303 phosphorylation are particularly pronounced during critical developmental windows. GRIN2B expression peaks during the third postnatal week in rodents, corresponding to a period of intense synaptogenesis and circuit refinement. Disruption during this period can have lasting effects on brain development and function .

What experimental approaches can distinguish between loss-of-function and gain-of-function GRIN2B variants regarding Ser1303 phosphorylation?

To accurately characterize GRIN2B variants as loss-of-function (LoF) or gain-of-function (GoF) with respect to Ser1303 phosphorylation, implement this multi-dimensional experimental strategy:

• Phosphorylation dynamics assessment:

  • Baseline phosphorylation: Quantify Ser1303 phosphorylation levels under basal conditions using Phospho-GRIN2B (Ser1303) Antibody

  • Stimulation response: Compare phosphorylation kinetics following activation of relevant kinases (CaMKII, PKC) between wild-type and variant GluN2B

  • Dephosphorylation rates: Measure the temporal dynamics of phosphatase-mediated dephosphorylation following kinase inhibition

• Functional correlation studies:

  • Electrophysiology: Record NMDAR-mediated currents in neurons expressing variant GluN2B, correlating current properties with phosphorylation status

  • Calcium imaging: Quantify NMDAR-dependent calcium influx and relate to Ser1303 phosphorylation levels

  • Some variants like N615I and V618G show reduced magnesium block sensitivity, suggesting gain-of-function effects that may interact with phosphorylation-dependent regulation

• Molecular interaction analysis:

  • Assess phosphorylation-dependent protein interactions using phosphomimetic (S1303D/E) or phosphodead (S1303A) mutations alongside the disease variants

  • Compare binding profiles of scaffolding proteins and signaling molecules that recognize phosphorylated Ser1303

  • Quantify differences in receptor internalization rates as a function of phosphorylation status

• Structural analysis integration:

  • Examine whether variants alter local protein flexibility using RMSF measurements from molecular dynamics simulations

  • Variants showing significantly different hydrogen bonding patterns (as observed with p.Asn615Ile, p.Thr685Pro, and p.Arg682Cys) may indicate structural changes affecting kinase access to Ser1303

  • Correlate protein compaction differences (measured by radius of gyration) with phosphorylation efficiency

• Developmental trajectory mapping:

  • Analyze phosphorylation patterns across developmental timepoints in cellular and animal models

  • Distinguish between variants that primarily affect initial phosphorylation versus those that disrupt phosphorylation-dependent developmental processes

What secondary antibodies are optimal for detection of Phospho-GRIN2B (Ser1303) Antibody in different applications?

The selection of appropriate secondary antibodies significantly impacts detection sensitivity and specificity when working with Phospho-GRIN2B (Ser1303) Antibody. Since this primary antibody is a rabbit polyclonal IgG, the following secondary antibodies are recommended for various applications:

For all applications, secondary antibodies that have been pre-adsorbed against other species' IgG are recommended to minimize cross-reactivity, especially in multi-labeling experiments. Additionally, including appropriate isotype controls (Rabbit IgG) is essential for distinguishing specific from non-specific binding .

What lysis conditions are critical for preserving Ser1303 phosphorylation during sample preparation?

Preserving the phosphorylation status at Ser1303 during sample preparation requires meticulous attention to lysis conditions and buffer composition:

• Phosphatase inhibitor cocktail: Include a comprehensive mix of phosphatase inhibitors targeting diverse phosphatase classes:

  • 50mM sodium fluoride (for serine/threonine phosphatases)

  • 10mM sodium pyrophosphate (for serine/threonine phosphatases)

  • 1mM sodium orthovanadate (for tyrosine phosphatases)

  • 10mM β-glycerophosphate (for serine/threonine phosphatases)

  • 1mM EDTA (for metal-dependent phosphatases)

  • Commercial phosphatase inhibitor cocktails containing additional inhibitors like okadaic acid

• Temperature control: Maintain samples at 4°C throughout all preparation steps to minimize phosphatase activity. Avoid room temperature incubations that accelerate dephosphorylation.

• Lysis buffer composition:

  • Use non-denaturing detergents like 1% NP-40 or 0.5% Triton X-100 that preserve protein-protein interactions

  • Include 150mM NaCl to maintain physiological ionic strength

  • Buffer at pH 7.4 using 50mM Tris-HCl or HEPES

  • Add 10% glycerol to stabilize proteins during freeze-thaw cycles

  • Include protease inhibitors (PMSF, leupeptin, aprotinin) to prevent proteolytic degradation

• Rapid processing: Minimize the time between tissue/cell harvesting and addition of lysis buffer. Flash-freeze samples that cannot be processed immediately.

• Homogenization technique: Use gentle homogenization methods (e.g., Dounce homogenizer) rather than sonication when possible, as excessive heat generated during sonication can activate phosphatases.

• Sample storage: Add sample buffer containing SDS and boil immediately after lysis to denature phosphatases, or store lysates at -80°C with phosphatase inhibitors if multiple analyses are planned .

How can Phospho-GRIN2B (Ser1303) Antibody be utilized in studying synaptic plasticity mechanisms?

The Phospho-GRIN2B (Ser1303) Antibody offers powerful capabilities for investigating synaptic plasticity mechanisms through multiple experimental paradigms:

Temporal phosphorylation dynamics: The antibody enables precise tracking of activity-dependent phosphorylation changes at Ser1303 following various stimulation protocols that induce long-term potentiation (LTP) or long-term depression (LTD). By collecting samples at different time points after stimulation (ranging from seconds to hours), researchers can correlate Ser1303 phosphorylation with specific phases of synaptic plasticity (induction, expression, maintenance) and determine the temporal relationship between this phosphorylation event and other molecular changes .

Subcellular compartment analysis: When combined with subcellular fractionation techniques or high-resolution imaging approaches, the antibody allows assessment of where within the neuron Ser1303 phosphorylation occurs following plasticity-inducing stimuli. This is particularly important for distinguishing between synaptic and extrasynaptic NMDA receptors, which can have opposing effects on neuronal survival and plasticity .

Intersection with other signaling pathways: The antibody can be used in multiplexed immunodetection approaches to simultaneously monitor Ser1303 phosphorylation alongside other key signaling events involved in synaptic plasticity, such as AMPA receptor phosphorylation, CaMKII activation, or CREB phosphorylation. This provides insights into how GRIN2B phosphorylation integrates with broader signaling networks .

Pharmacological intervention studies: When combined with selective inhibitors of specific kinases or phosphatases, the antibody helps delineate the precise enzymatic pathways regulating Ser1303 phosphorylation during different forms of synaptic plasticity, informing potential therapeutic targets for conditions with impaired plasticity .

What are the considerations for multiplex immunofluorescence imaging with Phospho-GRIN2B (Ser1303) Antibody?

Implementing multiplex immunofluorescence imaging with Phospho-GRIN2B (Ser1303) Antibody requires careful methodological considerations to achieve reliable co-localization data:

• Fixation protocol optimization:

  • Phospho-epitopes are particularly sensitive to fixation conditions

  • Test multiple fixation protocols (4% PFA for 10-20 minutes is typically a starting point)

  • Consider adding phosphatase inhibitors to fixation solutions

  • Evaluate methanol post-fixation for improved epitope accessibility while preserving phosphorylation

• Antibody compatibility planning:

  • Select co-staining antibodies raised in different host species to avoid cross-reactivity

  • When using multiple rabbit antibodies, employ sequential staining with direct labeling of the first primary antibody

  • Validate all antibodies individually before attempting multiplexing

  • Consider using monoclonal antibodies for non-phospho targets to reduce background

• Signal amplification strategies:

  • Implement tyramide signal amplification (TSA) for weak phospho-signals

  • Use high-sensitivity detection systems specifically designed for phospho-epitopes

  • Balance amplification with potential increases in background

• Controls for phospho-specificity:

  • Include lambda phosphatase-treated controls on separate slides/wells

  • Use tissue from kinase inhibitor-treated samples as negative controls

  • Include stimulated samples (e.g., glutamate-treated neurons) as positive controls

  • Employ phosphomimetic (S1303D) or phospho-null (S1303A) mutants in transfected cells as specificity controls

• Image acquisition parameters:

  • Use sequential scanning to eliminate channel bleed-through

  • Match acquisition parameters across all experimental conditions

  • Employ appropriate thresholding based on controls

  • Consider super-resolution techniques for precise co-localization with synaptic markers

• Quantification methodologies:

  • Develop unbiased quantification pipelines for co-localization analysis

  • Use appropriate statistical methods for co-localization measurement (Pearson's correlation, Manders' coefficient)

  • Implement automated image analysis when possible to reduce bias

  • Ensure adequate sampling across multiple cells, fields, and experimental replicates